Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,024 USD | -1.97% |
|
-4.40% | +16.60% |
07-03 | Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval | MT |
07-03 | Sanofi obtains EU approval for Dupixent | RE |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.60% | 113B | |
+15.58% | 122B | |
+17.55% | 26.22B | |
-24.33% | 19.01B | |
-19.14% | 15.71B | |
-17.95% | 15.22B | |
-46.81% | 14.72B | |
+58.78% | 14.58B | |
+4.91% | 13.84B | |
+100.06% | 10.4B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Transcript : Regeneron Pharmaceuticals, Inc. Presents at 36th Annual J.P. Morgan Healthcare Conference, Jan-08-2018 through Jan-11-2018